EUVIMEDEUVIMED entdecken
Crossref

YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma

Yan-Ling Zhou iD, Xiao-Lian Liu, Si-Si Huang, Gui-Ming Zhang, Xuan-Yu Jin, Liang Chen, Le Yu, Yi-Lei Li

Pigment Cell & Melanoma Research · 2025

DOI: 10.1111/pcmr.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Yan-Ling Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Drug Resistance, Neoplasm, Up-Regulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Yiyang Healthcare Charity Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BET inhibitors have the potential to treat malignant tumors via the epigenetic modification mechanism. Although BET inhibitors show promise as anticancer agents for uveal melanoma (UM), the emergence of acquired resistance significantly limits their clinical efficacy. We developed isogenic OTX015‐resistant UM cell models (OMM2.3R and OMM2.5R) via exposure to escalating OTX015 concentrations (0.04–0.5 μM over 6 months). These resistant cells demonstrated reduced sensitivity to OTX015‐induced cytotoxicity. Moreover, the migratory ability of resistant cells was less affected by OTX015 compared to parental cells. Transcriptome analysis revealed an upregulation of YAP‐activated genes in resistant cells. Notably, OTX015‐resistant cells retained sensitivity to YAP inhibition via shRNA or pharmacological inhibitors. This study establishes YAP activation as a novel compensatory mechanism driving BET inhibitor resistance in UM. These findings position YAP inhibition as a potential therapeutic target to overcome BET inhibitor resistance, with clinical translational potential for resistant UM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveal NeoplasmsMelanomaDrug Resistance, NeoplasmUp-RegulationTranscription FactorsAdaptor Proteins, Signal TransducingHeterocyclic Compounds, 3-RingPhosphoproteinsHumansUveal MelanomaCell Line, TumorYAP-Signaling ProteinsGene Expression Regulation, NeoplasticCell MovementCell Cycle ProteinsAcetanilidesBromodomain Containing ProteinsProteins

Stichwörter der Autor:innen

BET inhibitorsYAPdrug resistanceuveal melanomaverteporfin

Substanzen

YAP-Signaling ProteinsTranscription FactorsYAP1 protein, humanAdaptor Proteins, Signal TransducingOTX015Heterocyclic Compounds, 3-RingPhosphoproteinsCell Cycle Proteinsbromodomain and extra-terminal domain protein, humanAcetanilides

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
  • Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Yan-Ling Zhou

Förderung

  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Yiyang Healthcare Charity Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Y. L., Liu, X. L., Huang, S. S., Zhang, G. M., Jin, X. Y., Chen, L., Yu, L., & Li, Y. L. (2025). YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.70036

Vancouver

Zhou YL, Liu XL, Huang SS, Zhang GM, Jin XY, Chen L, et al. YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.70036

BibTeX
@article{Zhou2025,
  author = {Zhou, Yan-Ling and Liu, Xiao-Lian and Huang, Si-Si and Zhang, Gui-Ming and Jin, Xuan-Yu and Chen, Liang and Yu, Le and Li, Yi-Lei},
  title = {YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  doi = {10.1111/pcmr.70036}
}
Kostenlos starten →